What Are Physician and Payer Expectations as New Mechanisms of Action Transform the Market Landscape? Significant opportunity remains for therapies to treat moderate to severe ulcerative colitis (…
LaunchTrends: Anoro Ellipta Wave 2 is the second of a three-wave report series designed to track the postlaunch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment…
How Are Payers Responding to High-Cost Therapies on Their Exchange-Based Plans? The Affordable Care Act (ACA) has expanded access to insurance coverage to millions and has reformed health insurance…
Biosimilars are potentially disruptive to the pharmaceutical industry; the biosimilars sector not only allows extremely lucrative commercial opportunities for biosimilar companies but also poses an…
Last Updated 23 December 2014 Acute coronary syndrome (ACS)—an umbrella term that encompasses acute ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI),…
Last Updated 15 December 2014 Tumor necrosis factor (TNF)-α inhibitors continue to dominate the multibillion-dollar rheumatoid arthritis (RA) market. An increase in the prevalent RA population,…
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…
Last Updated 13 November 2014 The term dyslipidemia refers to abnormalities in the composition, concentration, or size of lipoproteins in the circulation. Dyslipidemia is a key modifiable risk…
Rheumatoid arthritis (RA) is a complex autoimmune condition characterized by chronic and progressive joint inflammation that typically results in permanent, debilitating tissue damage. Biological…
Earlier diagnosis and advances in treatment have reduced cancer patients’ mortality over the past decade in the mature markets. Developing markets will continue to see benefits in cancer survival…
With approximately 5 million patients diagnosed in the seven major pharmaceutical markets, epilepsy is a common, debilitating collection of seizure disorders that affect patients’ quality of life…
Last Updated 29 December 2014 In the simplest of terms, obesity is the result of an imbalance in energy intake versus expenditure, leading to excess energy stores in the form of body fat (adipose…
Last Updated 29 December 2014 Hepatitis C virus (HCV) is the leading cause of end-stage liver disease and hepatocellular carcinoma. Treatment of it represents a large untapped market owing to high…
Diabetes is a chronic, progressive metabolic disease in which the body lacks or is resistant to endogenous insulin, leading to a state of persistent high blood sugar (referred to as hyperglycemia…